Examination of the usefulness as the tumor marker of the NY-ESO-1 antibody titer in the esophageal cancer patient

Examination of the usefulness as the tumor marker of the NY-ESO-1 antibody titer in the esophageal cancer patient - Examination of the usefulness as the tumor marker of the NY-ESO-1 antibody titer in the esophageal cancer patient

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008997

Enrollment

400

Registered

2012-09-29

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are diagnosed as esophageal cancer which are proven by biopsy as squamous cell carcinoma or adenocarinoma and can receive radical resection.

Exclusion criteria

Exclusion criteria: Synchronous or metachronous (within 5 years) malignancies

Design outcomes

Primary

Measure	Time frame
Recurrence prediction by the NY-ESO-1 antibody titer in the esophageal cancer patients, with NY-ESO-1 antibody titer positive before surgery, that has been resected radically, NY-ESO-1 antibody titer was measured. We examine The recurrence rate of the NY-ESO-1 antibody-positive case of the first year after surgery.	—

Secondary

Measure	Time frame
1. NY-ESO-1 antibody titer positive rate 2. Incidence of the NY-ESO-1 antigen expression in the esphageal cancer tissue 3. Correlation between NY-ESO-1 antibody titer and prognosis 4. Correlation between expression of the NY-ESO-1 antigen and prognosis 5. Relations withNY-ESO-1 antibody titer and the effect of the chemotherapy	—

Countries

Japan

Outcome results